- Home
- BFRI vs PCSA Comparison
BFRI vs PCSA Comparison
Compare BFRI & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | PCSA |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | 93 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 8.0M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | BFRI | PCSA |
|---|---|---|
| Price | $0.85 | $2.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.75 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 480.9K | 37.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,000.00 |
| Revenue This Year | $11.37 | N/A |
| Revenue Next Year | $10.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.11 |
| 52 Week High | $1.18 | $8.88 |
Technical Indicators
Market Signals| Indicator | BFRI | PCSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 58.49 |
| Support Level | $0.81 | $0.21 |
| Resistance Level | $0.91 | $3.80 |
| Average True Range (ATR) | 0.07 | 0.28 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 46.44 | 79.62 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).